Search details
1.
Robust and prototypical immune responses toward COVID-19 vaccine in First Nations peoples are impacted by comorbidities.
Nat Immunol
; 24(6): 966-978, 2023 06.
Article
in English
| MEDLINE | ID: mdl-37248417
2.
CD8+ T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope display high naive precursor frequency and TCR promiscuity.
Immunity
; 54(5): 1066-1082.e5, 2021 05 11.
Article
in English
| MEDLINE | ID: mdl-33951417
3.
Human coronavirus OC43 nanobody neutralizes virus and protects mice from infection.
J Virol
; : e0053124, 2024 May 06.
Article
in English
| MEDLINE | ID: mdl-38709106
4.
Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice.
Proc Natl Acad Sci U S A
; 118(19)2021 05 11.
Article
in English
| MEDLINE | ID: mdl-33893175
5.
SARS-CoV-2 Omicron BA.1 Challenge after Ancestral or Delta Infection in Mice.
Emerg Infect Dis
; 28(11): 2352-2355, 2022 11.
Article
in English
| MEDLINE | ID: mdl-36191630
6.
A Randomized Trial of Two 2-Dose Influenza Vaccination Strategies for Patients Following Autologous Hematopoietic Stem Cell Transplantation.
Clin Infect Dis
; 73(11): e4269-e4277, 2021 12 06.
Article
in English
| MEDLINE | ID: mdl-33175132
7.
Persistence of SARS-CoV-2-Specific IgG in Children 6 Months After Infection, Australia.
Emerg Infect Dis
; 27(8): 2233-2235, 2021.
Article
in English
| MEDLINE | ID: mdl-34016252
8.
Convalescent plasma treatment for COVID-19: Tempering expectations with the influenza experience.
Eur J Immunol
; 50(10): 1447-1453, 2020 10.
Article
in English
| MEDLINE | ID: mdl-32886952
9.
Evaluation of Serological Tests for SARS-CoV-2: Implications for Serology Testing in a Low-Prevalence Setting.
J Infect Dis
; 222(8): 1280-1288, 2020 09 14.
Article
in English
| MEDLINE | ID: mdl-32761124
10.
How Live Attenuated Vaccines Can Inform the Development of Broadly Cross-Protective Influenza Vaccines.
J Infect Dis
; 219(Suppl_1): S81-S87, 2019 04 08.
Article
in English
| MEDLINE | ID: mdl-30715386
11.
Ancestral, Delta, and Omicron (BA.1) SARS-CoV-2 strains are dependent on serine proteases for entry throughout the human respiratory tract.
Med
; 4(12): 944-955.e7, 2023 Dec 08.
Article
in English
| MEDLINE | ID: mdl-37769654
12.
Antibody titres elicited by the 2018 seasonal inactivated influenza vaccine decline by 3 months post-vaccination but persist for at least 6 months.
Influenza Other Respir Viruses
; 17(1): e13072, 2023 01.
Article
in English
| MEDLINE | ID: mdl-36451293
13.
Comparative Longitudinal Serological Study of Anti-SARS-CoV-2 Antibody Profiles in People with COVID-19.
Microorganisms
; 11(8)2023 Aug 02.
Article
in English
| MEDLINE | ID: mdl-37630545
14.
Macrophage ACE2 is necessary for SARS-CoV-2 replication and subsequent cytokine responses that restrict continued virion release.
Sci Signal
; 16(782): eabq1366, 2023 04 25.
Article
in English
| MEDLINE | ID: mdl-37098119
15.
Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18-55 years or ≥56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trial.
EBioMedicine
; 97: 104842, 2023 Nov.
Article
in English
| MEDLINE | ID: mdl-37865043
16.
Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccine.
EBioMedicine
; 92: 104574, 2023 Jun.
Article
in English
| MEDLINE | ID: mdl-37148585
17.
Robust SARS-CoV-2 T cell responses with common TCRαß motifs toward COVID-19 vaccines in patients with hematological malignancy impacting B cells.
Cell Rep Med
; 4(4): 101017, 2023 04 18.
Article
in English
| MEDLINE | ID: mdl-37030296
18.
Interim results from a phase I randomized, placebo-controlled trial of novel SARS-CoV-2 beta variant receptor-binding domain recombinant protein and mRNA vaccines as a 4th dose booster.
EBioMedicine
; 98: 104878, 2023 Dec.
Article
in English
| MEDLINE | ID: mdl-38016322
19.
Long-Read RNA Sequencing Identifies Polyadenylation Elongation and Differential Transcript Usage of Host Transcripts During SARS-CoV-2 In Vitro Infection.
Front Immunol
; 13: 832223, 2022.
Article
in English
| MEDLINE | ID: mdl-35464437
20.
Biparatopic nanobodies targeting the receptor binding domain efficiently neutralize SARS-CoV-2.
iScience
; 25(11): 105259, 2022 Nov 18.
Article
in English
| MEDLINE | ID: mdl-36213007